Article Versions Notes

Tanimura K, Takeda T, Kataoka N, Yoshimura A, Nakanishi K, Yamanaka Y, Yoshioka H, Honda R, Uryu K, Fukui M, et al. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers. 2023; 15(20):4988. https://doi.org/10.3390/cancers15204988

Tanimura, Keiko, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, and et al. 2023. "First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study" Cancers 15, no. 20: 4988. https://doi.org/10.3390/cancers15204988